NKTR News and Press, Nektar Therapeutics From 04/20/22

Regenxbio holds the most powerful gene delivery platform on the planet. The company recently closed a $1.3B deal with AbbVie for the development of RGX314 for wet AMD. RGX202 is the hidden asset, poised to make waves in the coming years. For further details see: Regenxbi...

Whenever your stock tumbles due to a temporary issue, it will nearly always rebound at resolution in the ensuing months. Iovance Biotherapeutics' potency assay for lifileucel caused a huge haircut in the share price. As Iovance has now resolved the assay debacle, the stock is pois...

Stocks recorded fractional declines on Monday, bouncing around during the session as investors waited for signals from incoming earnings reports due out during the rest of the week.  Even with the general lack of direction, some stocks showed major moves on the back of news. This include...

Gainers: Casa Systems (CASA) +67%. CEL-SCI Corporation (CVM) +55%. Natus Medical (NTUS) +29%. Frequency Therapeutics (FREQ) +26%. GWG Holdings (GWGH) +20%. IMARA (IMRA) +19%. Iveda Solutions (IVDA) +18%. AgriFORCE (AGRI) +18%. Maris-Tech (MTEK) +17%. Tritium DCFC (DCFC) +12%. Losers...

Shares of Nektar Therapeutics (NASDAQ: NKTR) were crashing 35.2% lower as of 10:51 a.m. ET on Monday. The steep decline came after Nektar and Bristol Myers Squibb (NYSE: BMY) announced that they were ending the development program for bempegaldesleukin (bempeg) in combinatio...

Nektar Therapeutics (NASDAQ:NKTR) stock fell ~36% on April 18 after a downgrade by Goldman Sachs to Sell from Neutral following Nektar and Bristol Myers Squibb's (BMY) decision to terminate the bempegaldesleukin ((bempeg)) program. The firm said it is expecting Nektar's (NKTR) share...

Stock Market Today Mid-Morning Updates On Monday, the Dow Jones Industrial Average is down by 20 points as investors anticipate yet another slew of high-profile corporate earnings this week. This also comes after major banks like Morgan Stanley ( NYSE: MS ) and Goldman...

Gainers: Natus Medical (NTUS) +30%. MedAvail (MDVL) +25%. IMARA (IMRA) +13%. Frequency Therapeutics (FREQ) +11%. Lyra Therapeutics (LYRA) +4%. Losers: Nektar Therapeutics (NKTR) -36%. TG Therapeutics (TGTX) -24%. Lixte Biotechnology (LIXT) -15%.&#x...

TG Therapeutics (TGTX) -30% as it withdraws Ukoniq from sale, pulls filing with FDA. Nektar Therapeutics (NKTR) -21% after Nektar, Bristol Myers to end development program for bempegaldesleukin/Opdivo combo. DiDi Global (DIDI) -18% on Q4 earnings release and deli...

Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) PR Newswire PRINCETON, N.J. and SAN FRANCISCO , April 14, 2022 /PRNewswire/ -- Nektar Therapeutics ...